PDCD1 and neoplasm: Promising preclinical results using combination strategies, including dual checkpoint blockade targeting LAG-3 and TIM-3 alongside PD-1 inhibition, as well as epigenetic modulation with histone deacetylase inhibitors, offer hope for enhancing anti-tumor immunity.